Selumetinib is a MEK inhibitor used for the treatment of neurofibromatosis type 1 (NF1) in children 2 years and older who have plexiform neurofibromas (PNs) that cannot be removed by surgery. It is available under the brand name Koselugo and is prescribed in capsule form. Selumetinib works by targeting specific proteins involved in cell growth, helping to slow or shrink tumors associated with NF1. This medication is available only by prescription and is primarily used in pediatric patients.
![Methyl 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylate](https://veeprho.com/wp-content/uploads/2024/07/Methyl-5-4-broMo-2-chlorophenylamino-VE0020792.png "Methyl 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylate")
Parent: Selumetinib
![2-hydroxyethyl 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylate](https://veeprho.com/wp-content/uploads/2024/07/VE0020797-2-hydroxyethyl-5-4-bromo-2-chlorophenyl-amino-4-fluoro-1-methyl-1H.png "2-hydroxyethyl 5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylate")
Parent: Selumetinib
![5-((2,4-dichlorophenyl)(nitroso)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide](https://veeprho.com/wp-content/uploads/2024/07/Selumetinib-VE0020791.png "5-((2,4-dichlorophenyl)(nitroso)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzo[d]imidazole-6-carboxamide")
Parent: Selumetinib
![5-((2,4-dichlorophenyl)amino)-4-fluoro-N-(2-hydroxyethyl)-1-methyl-1H-benzo[d]imidazole-6-carboxamide](https://veeprho.com/wp-content/uploads/2024/07/VE0020788-5-2-4-dichlorophenyl-amino-4-fluoro-N-2-hydroxyethyl-1-methyl-1H-benzo-d-imidazole-6-carboxamide.png "5-((2,4-dichlorophenyl)amino)-4-fluoro-N-(2-hydroxyethyl)-1-methyl-1H-benzo[d]imidazole-6-carboxamide")
Parent: Selumetinib
![5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxamide](https://veeprho.com/wp-content/uploads/2024/07/VE0020785-5-4-bromo-2-chlorophenyl-amino-4-fluoro-1-methyl-1H-benzo-d-imidazole-6-carboxamide.png "5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxamide")
Parent: Selumetinib
![5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylic acid](https://veeprho.com/wp-content/uploads/2024/07/VE0020794-5-4-broMo-2-chlorophenylamino.png "5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxylic acid")
Parent: Selumetinib
![5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-nitroso-1H-benzo[d]imidazole-6-carboxamide](https://veeprho.com/wp-content/uploads/2025/09/VE0025351-5-4-bromo-2-chlorophenyl-amino-4-fluoro-N.png "5-((4-bromo-2-chlorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-nitroso-1H-benzo[d]imidazole-6-carboxamide")
Parent: Selumetinib
![5-((4-bromo-2-chlorophenyl)amino)-N-(2-(tert-butoxy)ethoxy)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxamide](https://veeprho.com/wp-content/uploads/2024/07/VE0020796-5-4-bromo-2-chlorophenyl-amino.png "5-((4-bromo-2-chlorophenyl)amino)-N-(2-(tert-butoxy)ethoxy)-4-fluoro-1-methyl-1H-benzo[d]imidazole-6-carboxamide")
Parent: Selumetinib
Impurities in Selumetinib may arise due to chemical synthesis, degradation, or storage conditions. Regulatory agencies such as the FDA, ICH, and EMA impose strict limits on impurity levels to ensure drug safety and efficacy.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Selumetinib is a MEK inhibitor that blocks the MEK1 and MEK2 enzymes, which are involved in cell growth and survival. By inhibiting these pathways, it helps slow tumor growth in patients with neurofibromatosis type 1 (NF1) and may reduce tumor size.
Koselugo (Selumetinib) is FDA-approved for the treatment of pediatric patients (ages 2 and older) with NF1-related plexiform neurofibromas (PNs) that cannot be surgically removed. It helps to reduce tumor size and improve symptoms such as pain and mobility issues.
Yes, clinical studies have shown that Selumetinib can shrink tumors in children with plexiform neurofibromas. Many patients experience a reduction in tumor volume and improvements in pain, mobility, and overall quality of life.
Selumetinib is a selective MEK1 and MEK2 inhibitor that works by:
